SE0102147D0 - New methods - Google Patents

New methods

Info

Publication number
SE0102147D0
SE0102147D0 SE0102147A SE0102147A SE0102147D0 SE 0102147 D0 SE0102147 D0 SE 0102147D0 SE 0102147 A SE0102147 A SE 0102147A SE 0102147 A SE0102147 A SE 0102147A SE 0102147 D0 SE0102147 D0 SE 0102147D0
Authority
SE
Sweden
Prior art keywords
methods
mnk2b
mnk2a
relates
new methods
Prior art date
Application number
SE0102147A
Other languages
English (en)
Inventor
Christina Bendz
Staffan Lake
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20284509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0102147(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE0102147A priority Critical patent/SE0102147D0/sv
Publication of SE0102147D0 publication Critical patent/SE0102147D0/sv
Priority to PT02739056T priority patent/PT1397681E/pt
Priority to DE60218843T priority patent/DE60218843T2/de
Priority to AT02739056T priority patent/ATE356995T1/de
Priority to CA002446284A priority patent/CA2446284A1/en
Priority to PCT/SE2002/001268 priority patent/WO2002103361A1/en
Priority to ES02739056T priority patent/ES2284879T3/es
Priority to EP02739056A priority patent/EP1397681B1/en
Priority to DK02739056T priority patent/DK1397681T3/da
Priority to US10/174,784 priority patent/US20030022241A1/en
Priority to JP2003505626A priority patent/JP4475945B2/ja
Priority to AU2002311737A priority patent/AU2002311737B2/en
Priority to CY20071100708T priority patent/CY1107640T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SE0102147A 2001-06-18 2001-06-18 New methods SE0102147D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE0102147A SE0102147D0 (sv) 2001-06-18 2001-06-18 New methods
AU2002311737A AU2002311737B2 (en) 2001-06-18 2002-06-18 Method for identification of agents for the treatment of diabetes
JP2003505626A JP4475945B2 (ja) 2001-06-18 2002-06-18 糖尿病処置のための作用物質同定法
PCT/SE2002/001268 WO2002103361A1 (en) 2001-06-18 2002-06-18 Method for identification of agents for the treatment of diabetes
DE60218843T DE60218843T2 (de) 2001-06-18 2002-06-18 Verfahren zur identifizierung von mitteln zur behandlung von diabetes
AT02739056T ATE356995T1 (de) 2001-06-18 2002-06-18 Verfahren zur identifizierung von mitteln zur behandlung von diabetes
CA002446284A CA2446284A1 (en) 2001-06-18 2002-06-18 Method for identification of agents for the treatment of diabetes
PT02739056T PT1397681E (pt) 2001-06-18 2002-06-18 Processos para a identificação de agentes para o tratamento de diabetes
ES02739056T ES2284879T3 (es) 2001-06-18 2002-06-18 Metodo para la identificacion de agentes para el tratamiento de la diabetes.
EP02739056A EP1397681B1 (en) 2001-06-18 2002-06-18 Method for identification of agents for the treatment of diabetes
DK02739056T DK1397681T3 (da) 2001-06-18 2002-06-18 Fremgangsmåde til identificering af midler til behandling af diabetes
US10/174,784 US20030022241A1 (en) 2001-06-18 2002-06-18 Methods
CY20071100708T CY1107640T1 (el) 2001-06-18 2007-05-25 Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102147A SE0102147D0 (sv) 2001-06-18 2001-06-18 New methods

Publications (1)

Publication Number Publication Date
SE0102147D0 true SE0102147D0 (sv) 2001-06-18

Family

ID=20284509

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102147A SE0102147D0 (sv) 2001-06-18 2001-06-18 New methods

Country Status (13)

Country Link
US (1) US20030022241A1 (sv)
EP (1) EP1397681B1 (sv)
JP (1) JP4475945B2 (sv)
AT (1) ATE356995T1 (sv)
AU (1) AU2002311737B2 (sv)
CA (1) CA2446284A1 (sv)
CY (1) CY1107640T1 (sv)
DE (1) DE60218843T2 (sv)
DK (1) DK1397681T3 (sv)
ES (1) ES2284879T3 (sv)
PT (1) PT1397681E (sv)
SE (1) SE0102147D0 (sv)
WO (1) WO2002103361A1 (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055664A2 (en) * 2001-01-12 2002-07-18 Exelixis, Inc. Modulating insulin receptor signaling
DE10294485T5 (de) 2001-10-29 2004-04-29 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind
US20050202407A1 (en) * 2003-12-01 2005-09-15 Baylor College Of Medicine Methods and assays for screening anti-neoplastic therapeutic agents
AU2005311684A1 (en) * 2004-12-02 2006-06-08 University Of Massachusetts Glucose-transport related genes, polypeptides, and methods of use thereof
EP1991547A2 (en) 2006-03-09 2008-11-19 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
AR080328A1 (es) 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EP2539344B1 (en) 2010-02-26 2014-10-15 Boehringer Ingelheim International GmbH Halogen or cyano substituted thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions
EA201201191A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
EP2917185B1 (en) 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015082324A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
CA2944103A1 (en) 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
KR20180073629A (ko) 2015-10-22 2018-07-02 셀비타 에스에이 피리돈 유도체 및 키나제 억제제로서의 그의 용도
WO2017165908A1 (en) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Method of inhibiting high fat diet-related conditions
US12031161B2 (en) 2020-10-09 2024-07-09 University Of Massachusetts Targeting Nrip1 to alleviate metabolic disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3

Also Published As

Publication number Publication date
PT1397681E (pt) 2007-06-19
JP4475945B2 (ja) 2010-06-09
WO2002103361A1 (en) 2002-12-27
DE60218843D1 (de) 2007-04-26
JP2005500033A (ja) 2005-01-06
DK1397681T3 (da) 2007-07-16
DE60218843T2 (de) 2007-07-12
AU2002311737B2 (en) 2007-06-21
CA2446284A1 (en) 2002-12-27
ES2284879T3 (es) 2007-11-16
ATE356995T1 (de) 2007-04-15
EP1397681B1 (en) 2007-03-14
EP1397681A1 (en) 2004-03-17
US20030022241A1 (en) 2003-01-30
CY1107640T1 (el) 2013-04-18

Similar Documents

Publication Publication Date Title
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
ATE408601T1 (de) Fredericamycin-derivate
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
ATE311148T1 (de) Chirurgische vorrichtungen
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
DE60309203D1 (de) Iontophoretische verabreichung von rotigotin zur behandlung der parkinson'schen krankheit
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
DE60137635D1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE69814394D1 (de) Verwendung von levobupivacain
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE60138189D1 (de) Eine neue verwendung von deferiprone
AU2003260436A1 (en) Pyrimidine compounds
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
TR199901385T2 (xx) Piperidin t�revleri.
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
SE0202608D0 (sv) New sequences